Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Hodi, Frank
Item TypeName
Academic Article Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.
Academic Article Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
Academic Article MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients.
Academic Article Genetically modified tumor cell vaccines.
Academic Article Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
Academic Article Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage.
Academic Article Molecular genetics of familial cutaneous melanoma.
Academic Article Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
Academic Article Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
Academic Article Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
Academic Article High-throughput oncogene mutation profiling in human cancer.
Academic Article Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis.
Academic Article Melanoma.
Academic Article Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.
Academic Article Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report.
Academic Article Combinatorial cancer immunotherapy.
Academic Article Cytotoxic T-lymphocyte-associated antigen-4.
Academic Article Improved survival with ipilimumab in patients with metastatic melanoma.
Academic Article Melanoma.
Academic Article Modulation of T-cell activation by malignant melanoma initiating cells.
Academic Article Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Academic Article Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Academic Article Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.
Academic Article KIT gene mutations and copy number in melanoma subtypes.
Academic Article Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.
Academic Article Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Academic Article CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.
Academic Article Defining the critical hurdles in cancer immunotherapy.
Academic Article From genes to drugs: targeted strategies for melanoma.
Academic Article Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Academic Article Cytotoxic T-lymphocyte-associated antigen-4.
Academic Article The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Academic Article Age as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Genoa, Italy
Academic Article Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
Academic Article When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
Academic Article Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
Academic Article Prevalance of antibodies to three retroviruses in a captive colony of Macaque monkeys
Academic Article Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.
Academic Article Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Academic Article Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Academic Article ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
Academic Article Improved endpoints for cancer immunotherapy trials.
Academic Article Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.
Academic Article Adjuvant high-dose interferon Alpha-2b in patients with high-risk melanoma
Academic Article Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.
Academic Article Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Academic Article BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
Academic Article Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in previously vaccinated melanoma and ovarian cancer patients
Academic Article Interleukins and Cancer. in Encyclopedia of Cancer
Academic Article Active immunotherapy induces antibody responses that target tumor angiogenesis.
Academic Article Modeling genomic diversity and tumor dependency in malignant melanoma.
Academic Article The biologic importance of tumor-infiltrating lymphocytes.
Academic Article Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.
Academic Article Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-?B pathways.
Academic Article Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
Academic Article Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys.
Academic Article Gender as a factory influencing the toxicity of adjuvant chemotherapy for colorectal cancer
Academic Article High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast cancer.
Academic Article c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
Academic Article Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Academic Article The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Academic Article Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Academic Article Combinatorial Cancer Immunotherapy. in Cancer Immunotherapy – a thematic volume of Advances in Immunology
Academic Article Skin cancer. in Atlas of Diagnostic Oncology
Academic Article Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.
Academic Article Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm.
Academic Article Overcoming immunological tolerance to melanoma: Targeting CTLA-4.
Academic Article Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
Academic Article Major response to imatinib mesylate in KIT-mutated melanoma.
Concept Colonic Neoplasms
Concept Breast Neoplasms
Concept Bone Neoplasms
Concept Head and Neck Neoplasms
Concept Immunotherapy, Active
Concept Neoplasms, Experimental
Concept Immunotherapy, Adoptive
Concept Colorectal Neoplasms
Concept Salivary Gland Neoplasms
Concept Cancer Vaccines
Concept Pancreatic Neoplasms
Concept Ovarian Neoplasms
Concept Kidney Neoplasms
Concept Vulvar Neoplasms
Concept Pleural Neoplasms
Concept Neoplasms, Multiple Primary
Concept Immunotherapy
Concept Brain Neoplasms
Concept Lung Neoplasms
Concept Uterine Neoplasms
Concept Rectal Neoplasms
Concept Skin Neoplasms
Concept Intestinal Neoplasms
Concept Neoplasms, Unknown Primary
Concept Neoplasms
Concept Central Nervous System Neoplasms
Concept Urologic Neoplasms
Concept Eye Neoplasms
Concept Uterine Cervical Neoplasms
Concept Soft Tissue Neoplasms
Concept Liver Neoplasms
Concept Prostatic Neoplasms
Concept Hematologic Neoplasms
Concept Uveal Neoplasms
Academic Article Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.
Academic Article Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
Academic Article Ipilimumab and its toxicities: a multidisciplinary approach.
Academic Article Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Academic Article Ipilimumab for patients with advanced mucosal melanoma.
Academic Article Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Academic Article Melanoma, version 2.2013: featured updates to the NCCN guidelines.
Academic Article Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.
Academic Article Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Academic Article Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
Academic Article The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
Academic Article Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
Academic Article CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Academic Article Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Academic Article A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Academic Article Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence.
Academic Article Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.
Academic Article Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Academic Article Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.
Academic Article Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.
Academic Article Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Academic Article Hematology/Oncology Clinics of North America. Melanoma. Preface.
Academic Article Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Academic Article Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Academic Article Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?
Academic Article The role of whole brain radiation therapy in the management of melanoma brain metastases.
Academic Article Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Academic Article Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
Academic Article Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
Academic Article Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Academic Article Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.
Academic Article Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanoma.
Academic Article Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.
Academic Article Treatment for advanced melanoma: new drugs, new opportunities, new challenges.
Academic Article Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Academic Article The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.
Academic Article Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
Academic Article Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
Academic Article Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
Academic Article Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.
Academic Article Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
Academic Article Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Academic Article Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
Academic Article Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Academic Article Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines.
Academic Article Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.
Academic Article Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Academic Article Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Academic Article Response assessment criteria for brain metastases: proposal from the RANO group.
Academic Article Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
Academic Article Corticosteroids and immune checkpoint blockade.
Academic Article Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Academic Article Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
Academic Article PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
Academic Article Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Academic Article Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
Academic Article Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Academic Article Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Academic Article Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.
Academic Article Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Academic Article STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Academic Article Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Academic Article Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Academic Article Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
Academic Article RECIST 1.1-Update and clarification: From the RECIST committee.
Academic Article RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.
Academic Article Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.
Academic Article Landscape of tumor-infiltrating T cell repertoire of human cancers.
Academic Article Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.
Academic Article Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.
Academic Article Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
Academic Article Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
Academic Article Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Academic Article Cancer immunotherapy trials: leading a paradigm shift in drug development.
Academic Article Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.
Academic Article Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.
Academic Article Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Academic Article Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Grant CTLA-4 Blockade in GM-CSF Vaccinated Patients
Grant MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATION
Grant Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV Melanoma
Academic Article Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Academic Article PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Academic Article Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation.
Academic Article Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Academic Article VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
Academic Article A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
Academic Article Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.
Academic Article An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
Academic Article Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
Academic Article Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.
Academic Article Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.
Academic Article Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Academic Article Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients.
Academic Article Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma.
Academic Article Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
Academic Article CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.
Academic Article Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
Academic Article Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line.
Academic Article Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Academic Article Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Academic Article Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Academic Article Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.
Academic Article Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Academic Article Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Academic Article Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.
Academic Article Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA).
Academic Article Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody.
Academic Article Combination immunotherapy: a road map.
Academic Article Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
Academic Article iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Academic Article Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.
Academic Article Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
Academic Article Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Academic Article Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
Academic Article Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Academic Article Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.
Academic Article Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
Academic Article Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Academic Article Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation.
Academic Article Health-related quality of life results from the phase III CheckMate 067 study.
Academic Article Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
Academic Article Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.
Academic Article Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.
Academic Article A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Academic Article Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Academic Article Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.
Grant 3D Models of Immunotherapy
Academic Article Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Academic Article Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Academic Article Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Academic Article Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Grant Cancer Immune Monitoring and Analysis Center
Academic Article Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Academic Article Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.
Academic Article Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Academic Article Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
Academic Article Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
Academic Article Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Academic Article Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Academic Article Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Academic Article Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.
Academic Article Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
Academic Article Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Academic Article Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization.
Academic Article Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.
Academic Article Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.
Academic Article Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
Academic Article Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.
Academic Article Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Academic Article An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Academic Article MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Academic Article Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
Academic Article Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Academic Article Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Academic Article Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Academic Article Characterization of the Neuroendocrine Tumor Immune Microenvironment.
Academic Article Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
Academic Article Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.
Academic Article Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Academic Article Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Academic Article Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
Academic Article The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors.
Academic Article A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Academic Article Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Academic Article Imaging of Cancer Immunotherapy: Current Approaches and Future Directions.
Academic Article Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Academic Article Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.
Academic Article irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Academic Article Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
Academic Article Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Academic Article Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Academic Article The Intersection between Tumor Angiogenesis and Immune Suppression.
Academic Article Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition.
Academic Article Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features.
Academic Article Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Academic Article The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.
Academic Article Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
Academic Article Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Academic Article Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Academic Article Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.
Academic Article Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
Academic Article Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.
Academic Article Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Grant Biomaterials to Create T Cell Immunity
Academic Article Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Academic Article Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.
Academic Article Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Academic Article Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade.
Academic Article A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors.
Academic Article Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
Academic Article Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.
Academic Article Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
Academic Article Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Academic Article Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
Academic Article Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Academic Article Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases.
Academic Article Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Academic Article Drug-Related Pneumonitis in the Era of Precision Cancer Therapy.
Academic Article Author Correction: From genes to drugs: targeted strategies for melanoma.
Search Criteria
  • Cancer
  • immunotherapy
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.